AGIOAGIOS PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of AGIOS PHARMACEUTICALS, INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGIO본 종목 | $1.9B#9 | — | 1.8x#3 | 34.5x#8 | 48.0%#6 | -161.3%#13 | -873.9%#9 | -40.3%#7 | — | — | -22.2%#10 | — |
| ZYME | $2.1B#1 | — | 26.6x#12 | 20.2x#6 | 38.9%#8 | 33.9%#4 | -87.3%#6 | -100.9%#10 | — | — | 59.5%#3 | — |
| SEPN | $2.0B#2 | — | 5.3x#6 | 44.4x#9 | 4174.5%#1 | 31.9%#5 | -148.6%#7 | -12.6%#4 | — | — | 118.1%#2 | — |
| TRVI | $2.0B#3 | — | 6.1x#7 | — | — | 10.7%#7 | — | -13.3%#5 | — | — | 29.6%#4 | — |
| SRPT | $2.0B#4 | — | 1.3x#1 | 1.1x#1 | 4.3%#11 | -403.3%#14 | -37.5%#4 | -46.7%#8 | -73.0%#3 | — | — | — |
| BRVE | $1.9B#6 | — | — | — | — | — | — | — | — | — | — | — |
| XERS | $1.9B#7 | — | — | 6.5x#4 | 43.7%#7 | 101.0%#1 | 8.5%#1 | — | 20.6%#1 | — | 4.6%#5 | — |
| PGEN | $1.9B#8 | — | 43.1x#13 | 194.1x#11 | 146.7%#4 | -98.6%#10 | -1141.1%#10 | -575.1%#13 | -91.2%#5 | — | — | — |
| ZBIO | $1.8B#10 | — | 7.5x#9 | 184.9x#10 | 100.0%#5 | -140.6%#11 | -3830.6%#11 | -152.9%#12 | -296.6%#6 | — | -9.2%#8 | — |
| SLS | $1.8B#11 | — | 13.0x#11 | — | -100.0%#12 | 13.0%#6 | — | -19.5%#6 | — | — | 392.8%#1 | — |
| GENB | $1.8B#12 | — | 3.9x#4 | — | — | — | — | 0.0%#1 | — | — | — | — |
| STOK | $1.8B#13 | — | 5.0x#5 | 9.6x#5 | 404.5%#3 | 92.3%#2 | -11.2%#3 | -2.0%#2 | — | — | 3.4%#6 | — |
| TRAX | $1.9B#5 | — | 12.9x#10 | — | — | -1.5%#9 | — | -110.0%#11 | — | — | — | — |
| NUVB | $1.6B#14 | — | 6.5x#8 | 26.2x#7 | 699.0%#2 | 64.0%#3 | -338.7%#8 | -80.6%#9 | -87.4%#4 | — | -9.0%#7 | — |
| SUPN | $1.6B#15 | — | 1.5x#2 | 2.3x#2 | 8.6%#10 | -152.2%#12 | -8.7%#2 | -3.6%#3 | -4.8%#2 | — | -9.7%#9 | — |
| RARE | $1.6B#16 | — | — | 2.4x#3 | 20.2%#9 | -1.1%#8 | -79.5%#5 | — | — | — | -50.3%#11 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice